U.S. Markets close in 6 hrs 4 mins
  • S&P 500

    +1.23 (+0.03%)
  • Dow 30

    +70.17 (+0.23%)
  • Nasdaq

    +32.12 (+0.26%)
  • Russell 2000

    +3.59 (+0.20%)
  • Crude Oil

    -0.22 (-0.49%)
  • Gold

    +7.70 (+0.42%)
  • Silver

    -0.08 (-0.35%)

    +0.0047 (+0.3892%)
  • 10-Yr Bond

    -0.0270 (-2.85%)
  • Vix

    -0.27 (-1.28%)

    +0.0090 (+0.6746%)

    -0.6030 (-0.5775%)

    +398.84 (+2.10%)
  • CMC Crypto 200

    +5.84 (+1.56%)
  • FTSE 100

    -2.60 (-0.04%)
  • Nikkei 225

    +8.39 (+0.03%)

Why Intra-Cellular Therapies (ITCI) Might Surprise This Earnings Season

Zacks Equity Research
·2 min read

Investors are always looking for stocks that are poised to beat at earnings season and Intra-Cellular Therapies, Inc. ITCI may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Intra-Cellular Therapies is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ITCI in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 67 cents per share for ITCI, compared to a broader Zacks Consensus Estimate of a loss of 79 cents per share. This suggests that analysts have very recently bumped up their estimates for ITCI, giving the stock a Zacks Earnings ESP of +15.55% heading into earnings season.

Intra-Cellular Therapies Inc. Price and EPS Surprise

Intra-Cellular Therapies Inc. Price and EPS Surprise
Intra-Cellular Therapies Inc. Price and EPS Surprise

Intra-Cellular Therapies Inc. price-eps-surprise | Intra-Cellular Therapies Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that ITCI has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Intra-Cellular Therapies, and that a beat might be in the cards for the upcoming report.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report
To read this article on Zacks.com click here.